Tirzepatide in PWS, HO and GNSO

NCT06901245 · Recruiting

Last updated 2026-05-28

This clinical trial is testing the medication tirzepatide to see how it affects weight in adults with Prader-Willi Syndrome, hypothalamic obesity, or general obesity.

Status Recruiting Currently enrolling participants.

Phase Phase 4 Monitors a drug already on the market.

Type Interventional (clinical trial)

Design Non-randomized, open-label (no blinding) treatment study

Participants 36 people Planned (estimated).

Who can join Ages 18–26 · all sexes

Timeline Started 2025-05 · est. completion 2026-12

Where 3 sites · United States

What this study is testing ClinicalTrials.gov NCT06901245 ↗

Description as written by the study sponsor.

This research study is comparing the effectiveness of a weight loss medication called Tirzepatide in young adults with Prader-Willi Syndrome and/or hypothalamic obesity, as compared to young adults with obesity that is unrelated to a genetic syndrome or underlying medical cause. These groups will be given medication for 1 year to see how weight and other health factors are effected by the medication.

Treatments tested

Tirzepatide Drug

Subjects will take Tirzepatide for 48 weeks

Main thing measured	Change in weight
Sponsor	Grace Kim
Conditions studied	Prader-Willi Syndrome, Hypothalamic Obesity, Obesity/Therapy
GLP-1 drugs	tirzepatide

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT06901245 ↗